CRL · News · 20260805N
Guidance and Outlook
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-08-05 · Importance 56 · Surprise 68 · No source text
Charles River raised its 2026 organic revenue growth outlook to 0.0%–1.0% and adjusted EPS guidance to $11.15–$11.45. Management attributed the improved outlook to recovering biotech demand, particularly in Discovery and Safety Assessment (DSA), and stronger Manufacturing performance. The company also indicated that divestitures and cost actions should support margin expansion, although GAAP EPS guidance was reduced because of divestiture-related losses.
Key facts
- The company raised its 2026 organic revenue growth guidance to a range of 0.0%–1.0%. source
- Charles River's 2026 adjusted (non-GAAP) EPS guidance range: $11.15 to $11.45. source
- Seeking Alpha reported CRL raised 2026 guidance and expects EPS of $11.15–$11.45 and slightly positive organic growth. source
- Trading commentary noted CRL beat Q2 organic revenue and non-GAAP EPS expectations, prompting a raised 2026 guidance and margin expansion plans via strategic divestitures and technology investments. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | +0.3% | The company raised its 2026 organic revenue growth guidance to a range of 0.0%–1.0%. |
| net_income | unclear | probable | — | Charles River's 2026 adjusted (non-GAAP) EPS guidance range: $11.15 to $11.45. |